Skip to main content
Premium Trial:

Request an Annual Quote

GVK Bio, Crelux Partner on Drug Discovery Platform

NEW YORK (GenomeWeb News) - GVK Biosciences is collaborating with Crelux to offer biopharmaceutical companies an integrated drug discovery and development platform for use in structure-based drug design programs, Hyderabad, India-based GVK Bio said today.

GVK Bio will conduct in silico, in vitro, and in vivo studies and functions related to preclinical candidate nomination, while Munich-based Crelux will perform multifaceted structural studies toward X-ray elucidation of fragment or lead target complexes.

GVK said that the integrated offering may be used in "all aspects of structure-based drug design" and it offers "accelerated timelines for moving molecules from concept into the clinic at an optimal cost."

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.